Boehringer Ingelheim is inviting researchers to submit innovative proposals for clinically relevant systems that model acquired resistance to PD-1/ICB therapies in lung cancer, driven by tumor-intrinsic pathways or the immunosuppressive tumor microenvironment.
Public source
Publisher name
Public post
While immune checkpoint blockade (ICB) therapies targeting the PD-1/PD-L1 axis have transformed lung cancer treatment, acquired resistance remains a major challenge. Imp…
Company
Boehringer Ingelheim
- Industry
- Pharmaceutical Manufacturing
- Location
- Ingelheim am Rhein, DE
- Company size
- 10,001+ employees
About Boehringer Ingelheim
Our people are our strength. And together with over 54,000 colleagues, we're creating the next breakthrough in the world of healthcare and innovation for both humans and animals. Are you ready to join us? #LifeForward Privacy Notice: https://www.boehringer-ingelheim.com/privacy-notice Imprint: https://www.boehringer-ingelheim.com/imprint
See moreLatest activity
Latest activity from Boehringer Ingelheim
43 signals
Products & Services
Boehringer Ingelheim offers BI-7828, a potent MDM2-p53 antagonist that reactivates p53 signaling in TP53 wild-type tumors.
Products & Services
Boehringer Ingelheim is inviting experts to propose bold concepts for an autonomous small-molecule synthesis platform encompassing the complete Make phase from reagent handling to delivery of purified compounds.
Products & Services
Boehringer Ingelheim offers BI-7828, a potent MDM2-p53 antagonist that reactivates p53 signaling in TP53 wild-type tumors.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
AstraZeneca
AstraZeneca is working on potential new treatment options and combinations to support lung cancer care.
Research & Knowledge
Pierre Fabre Oncology
Pierre Fabre Oncology conducted a project with Laboratoires Pierre Fabre and Filière Intelligence Artificielle & Cancers in NSCLC to describe the molecular testing pathway and identify factors impacting therapeutic decisions.
Research & Knowledge
Servier
Servier's R&D budget is 70% dedicated to oncology with a strong focus on rare cancers.
Research & Knowledge
Pfizer
Pfizer will present at the WCLC26 conference on the analysis of the phase 3 CROWN study findings using early on-treatment AI-based imaging measures and ctDNA in patients with advanced ALK-positive NSCLC.
Research & Knowledge
IQVIA Laboratories